0001104659-23-129243.txt : 20231226 0001104659-23-129243.hdr.sgml : 20231226 20231226170122 ACCESSION NUMBER: 0001104659-23-129243 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231222 FILED AS OF DATE: 20231226 DATE AS OF CHANGE: 20231226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rubin Jonathan CENTRAL INDEX KEY: 0001836067 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 231513892 BUSINESS ADDRESS: BUSINESS PHONE: 3018382500 MAIL ADDRESS: STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC. STREET 2: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 4 1 tm2333640-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-12-22 0 0001356576 SUPERNUS PHARMACEUTICALS, INC. SUPN 0001836067 Rubin Jonathan C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE ROCKVILLE MD 20850 0 1 0 0 Sr. VP, Chief Medical Officer 0 Common Stock 2023-12-22 4 M 0 600 0 A 3447 D Common Stock 2023-12-22 4 F 0 204 27.66 D 3243 D Performance Share Unit 0 2023-12-22 4 M 0 600 0 D Common Stock 600 0 D Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. /s/ Timothy C. Dec, as attorney-in-fact 2023-12-26